Simulations Plus (NASDAQ:SLP) Issues FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.070-1.200 for the period, compared to the consensus EPS estimate of 0.900. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.7 million. Simulations Plus also updated its FY25 guidance to $1.07-$1.20 EPS.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on SLP shares. Stephens started coverage on Simulations Plus in a report on Friday, November 15th. They set an “overweight” rating and a $39.00 target price for the company. BTIG Research cut their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, October 24th. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, November 6th. Finally, StockNews.com lowered Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Simulations Plus has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Simulations Plus Stock Performance

Shares of NASDAQ:SLP opened at $30.39 on Wednesday. Simulations Plus has a 52-week low of $27.07 and a 52-week high of $51.22. The company has a market cap of $610.38 million, a P/E ratio of 62.02 and a beta of 0.80. The stock’s 50-day moving average is $29.78 and its 200-day moving average is $34.16.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The company had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. During the same period in the previous year, the business posted $0.18 EPS. The company’s revenue for the quarter was up 19.9% on a year-over-year basis. As a group, equities analysts predict that Simulations Plus will post 1.1 EPS for the current year.

Insider Buying and Selling

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $31.76, for a total value of $635,200.00. Following the completion of the transaction, the director now owns 3,442,584 shares in the company, valued at approximately $109,336,467.84. This represents a 0.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 19.40% of the stock is owned by company insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.